Resmed says it’s off to a strong start with 9% increase in revenue 

SAN DIEGO – Resmed reported revenue of $1.9 billion for the first quarter of fiscal year 2026, a 9% increase compared to the same period in 2025. 

“Our fiscal year 2026 is off to a strong start, with first-quarter performance reflecting continued progress toward our mission of helping people sleep better, breathe better and live longer and healthier, with care provided in their own home,” said Resmed’s Chairman and CEO Mick Farrell. 

Other financial results: 

• Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% 
• Income from operations increased 15%; non-GAAP income from operations up 19% 
• Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 
• Operating cash flow of $457 million 

Resmed also recorded $16 million of restructuring-related charges following company-wide workforce planning activities aligned with its 2030 strategic priorities. Restructuring charges were comprised of employee severance and other one-time termination benefits. 

The company included as highlights for the quarter: 

• Announced publication of a landmark study in The Lancet Respiratory Medicine projecting ~77 million U.S. adults with OSA by 2050 (~35% relative increase vs. 2020), underscoring the need for earlier diagnosis and scalable care pathways. 
• Received dual Red Dot Product Design 2025 awards for the AirTouch N30i (Innovative Products; Medical Design & Healthcare), reinforcing patient-centered innovation and adherence-focused design. 
• Launched the Sleep Institute, a global clinical insights initiative debuting at World Sleep Congress 2025 to publish independent research and inform policy and care model innovation that elevates sleep health as a public health priority. 
• Announced the election of Nicole Mowad-Nassar to Resmed’s board (effective Aug. 15, 2025) and the upcoming retirement of Rich Sulpizio (not standing for reelection at the Nov. 19, 2025, Annual Meeting).